Cargando…

Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling

BACKGROUND: Profound chemoresistance remains an intractable obstacle in pancreatic cancer treatment. Pancreatic cancer stem cells (CSCs) and the ubiquitous hypoxic niche have been proposed to account for drug resistance. However, the mechanism involved requires further exploration. This study invest...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zhengle, Han, Han, Rong, Yuping, Zhu, Kongfan, Zhu, Zhongchao, Tang, Zhigang, Xiong, Chenglong, Tao, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263055/ https://www.ncbi.nlm.nih.gov/pubmed/30486896 http://dx.doi.org/10.1186/s13046-018-0972-3

Ejemplares similares

Genes Modulating Butyrate Metabolism for Assessing Clinical Prognosis and Responses to Systematic Therapies in Hepatocellular Carcinoma
por: Chuanbing, Zhao, et al.
Publicado: (2022)

Up‐regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine‐resistant pancreatic cancer cells
por: Zhao, Hengqiang, et al.
Publicado: (2017)

ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer
por: Zhao, Hengqiang, et al.
Publicado: (2019)

Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine
por: Yin, Tao, et al.
Publicado: (2016)

Alterations of oral microbiota are associated with the development and severity of acute pancreatitis
por: Liu, Yiting, et al.
Publicado: (2023)

Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells
por: Li, Hehe, et al.
Publicado: (2019)

Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells
por: Li, Hehe, et al.
Publicado: (2023)

Astaxanthin inhibits gemcitabine-resistant human pancreatic cancer progression through EMT inhibition and gemcitabine resensitization
por: Yan, Tao, et al.
Publicado: (2017)

Inhibition of Notch activity promotes pancreatic cytokeratin 5-positive cell differentiation to beta cells and improves glucose homeostasis following acute pancreatitis
por: Zhang, Xiaoyi, et al.
Publicado: (2021)

PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer
por: Li, Wenbin, et al.
Publicado: (2020)

Wogonin increases gemcitabine sensitivity in pancreatic cancer by inhibiting Akt pathway
por: Zhang, Tianli, et al.
Publicado: (2022)

RRP9 promotes gemcitabine resistance in pancreatic cancer via activating AKT signaling pathway
por: Zhang, Zhiqi, et al.
Publicado: (2022)

Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma
por: Takagi, Tadataka, et al.
Publicado: (2023)

Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer
por: Massihnia, Daniela, et al.
Publicado: (2017)

Mechanistic Evaluation and Translational Signature of Gemcitabine-induced Chemoresistance by Quantitative Phosphoproteomics Analysis with iTRAQ Labeling Mass Spectrometry
por: Duan, Qingke, et al.
Publicado: (2017)

Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma
por: Okuno, Keisuke, et al.
Publicado: (2022)

Gemcitabine plus S-1 for metastatic pancreatic cancer
por: Zhu, Hong, et al.
Publicado: (2018)

FKBP5 as a Selection Biomarker for Gemcitabine and Akt Inhibitors in Treatment of Pancreatic Cancer
por: Hou, Junmei, et al.
Publicado: (2012)

Regulating glioma stem cells by hypoxia through the Notch1 and Oct3/4 signaling pathway
por: Zeng, Fei, et al.
Publicado: (2018)

Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling
por: Cui, Jing, et al.
Publicado: (2021)

Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia
por: Maftouh, M, et al.
Publicado: (2014)

Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway
por: Namba, T, et al.
Publicado: (2015)

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
por: Zhu, Zhou, et al.
Publicado: (2023)

Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
por: Ouyang, Guoqing, et al.
Publicado: (2016)

Enhancing efficacy of gemcitabine in pancreatic patient-derived xenograft mouse models
por: Inkoom, Andriana, et al.
Publicado: (2020)

Notch signaling, hypoxia, and cancer
por: Guo, Mingzhou, et al.
Publicado: (2023)

Huaier increases the antitumor effect of gemcitabine on pancreatic cancer in vitro and in vivo
por: Chen, Tao, et al.
Publicado: (2021)

Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer
por: Eto, K, et al.
Publicado: (2013)

microRNA-21-5p from M2 macrophage-derived extracellular vesicles promotes the differentiation and activity of pancreatic cancer stem cells by mediating KLF3
por: Chang, Jian, et al.
Publicado: (2021)

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
por: Cham, K K Y, et al.
Publicado: (2010)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

Isolation of Pancreatic Progenitor Cells with the Surface Marker of Hematopoietic Stem Cells
por: Ma, Fengxia, et al.
Publicado: (2012)

Specific inhibitor of Notch-3 enhances the sensitivity of NSCLC cells to gemcitabine
por: Hu, Bi-Dan, et al.
Publicado: (2018)

Gold Nanoparticles sensitize pancreatic cancer cells to gemcitabine
por: Huai, Yanyan, et al.
Publicado: (2019)

Bufalin suppresses cancer stem-like cells in gemcitabine-resistant pancreatic cancer cells via Hedgehog signaling
por: Wang, Haiyong, et al.
Publicado: (2016)

Thymoquinone affects the gemcitabine sensitivity of pancreatic cancer by regulating collagen via hypoxia inducible factor-1α
por: Zhao, Zhanxue, et al.
Publicado: (2023)

Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells
por: Zhu, Xu, et al.
Publicado: (2018)

Hypoxia Upregulates NOTCH3 Signaling Pathway to Promote Endothelial-Mesenchymal Transition in Pulmonary Artery Endothelial Cells
por: Wang, Li-Le, et al.
Publicado: (2021)

Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer
por: Inkoom, Andriana, et al.
Publicado: (2023)

GATA1 Promotes Gemcitabine Resistance in Pancreatic Cancer through Antiapoptotic Pathway
por: Chang, Zhenyu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dh32b6qvsmn4r45iu873deomsp